Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for statin
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages.In this meta-analysis, randomised trials (...) of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment duration of at least 2 years. We analysed individual participant data from 22 trials (n=134 537) and detailed summary data from one trial (n=12 705) of statin therapy versus control, plus individual participant data from five trials of more intensive versus less intensive statin therapy (n=39 612). We subdivided participants into six age groups (55 years or younger, 56-60 years, 61-65 years, 66
Statins are of no benefit in acute respiratory distress syndrome Statins are of no benefit in acute respiratory distress syndrome Discover Portal Discover Portal Statins are of no benefit in acute respiratory distress syndrome Published on 13 March 2018 doi: Giving statins to patients with acute respiratory distress syndrome made no difference to the number of days they spent on a ventilator. It also had no effect on mortality or the length of time spent in intensive care or in hospital (...) compared with placebo. In acute respiratory distress syndrome, the lungs become severely inflamed, fill with fluid (pulmonary oedema) and can no longer function. The person needs mechanical ventilation and is at high risk of multiple organ failure and mortality. This serious condition has high impact on both patients and NHS resources. Early studies had suggested statins may help to reverse the inflammatory process and could be a potential treatment to explore. This large, multicentre trial, funded
A statin drug during admission for heart surgery did not prevent an irregular heart beat A statin drug during admission for heart surgery did not prevent an irregular heart beat Discover Portal Discover Portal A statin drug during admission for heart surgery did not prevent an irregular heart beat Published on 14 July 2016 doi: The statin, rosuvastatin, taken by adults before and after heart surgery, did not prevent atrial fibrillation or heart muscle injury compared to placebo. Acute kidney (...) to reduce atrial fibrillation, nor heart muscle damage. It did, as expected, reduce “bad” cholesterol and C-reactive protein, a marker of inflammation, compared to the inactive placebo. Statins do have proven longer term benefits in reducing further damage to the coronary arteries and deaths from heart disease. Share your views on the research. Why was this study needed? Atrial fibrillation can occur in about 20% of people undergoing heart surgery and if not corrected is associated with poorer recovery
People take prescribed statins more reliably after discussing their advantages and disadvantages People take prescribed statins more reliably after discussing their advantages and disadvantages Discover Portal Discover Portal People take prescribed statins more reliably after discussing their advantages and disadvantages Published on 11 September 2018 doi: Patients want to know more about how statins work, the reasons for prescribing them and their possible side effects. Statins lower (...) cholesterol and reduce the risk of recurrent stroke or heart attack. They also help prevent cardiovascular disease developing in people at high risk. At a population, level statins reduce the overall incidence of cardiovascular disease for people at moderate risk, but the benefits for an individual are less clear-cut. This review found that people are happy to take statins if they believe they will prolong good quality of life. Barriers include mistrust and scepticism about over-prescribing. Worry about
On the history of statins On the History of Statins – Clinical Correlations Search On the History of Statins January 11, 2019 6 min read By David Pineles, MD Peer Reviewed With the implementation of the ACC/AHA guidelines on assessment of cardiovascular risk, . Dr. John Ioadnnidis, in an article published in JAMA in February 2014, estimated that under the new guidelines approximately 1 billion people worldwide would qualify to be prescribed a statin . With such a large number (...) of individuals taking this medication, it begs the question: where did statins come from? The story begins with famous German pathologist Rudolf Virchow. In the mid-19th century, Virchow discovered that cholesterol was found in the arterial walls of individuals that died from vaso-occlusive diseases such as myocardial infarction . In 1913, Russian pathologist Nikolai Anitschkow, the first person to describe foam cells , in a brilliant study, demonstrated cholesterol’s role in the development
Statins for the primary prevention of cardiovascular events 2019 www.kce.fgov.be KCE REPORT 306 STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS 2019 www.kce.fgov.be KCE REPORT 306 HEALTH TECHNOLOGY ASSESSMENT STATINS FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS AUDREY CORDON, CHRISTOPHE DE MEESTER, SOPHIE GERKENS, DOMINIQUE ROBERFROID, CHRIS DE LAET COLOPHON Title: Statins for the primary prevention of cardiovascular events Authors: Audrey Cordon (KCE), Christophe De Meester (...) Générale), Christiaan Vrints (UZA – Universitair Ziekenhuis Antwerpen) External validators: Guy De Backer (Ugent), Oscar Franco (University of Bern), Bert Vaes (KULeuven) Reported interests: All experts and stakeholders consulted within this report were selected because of their involvement in the topic of ‘Statins’. Therefore, by definition, each of them might have a certain degree of conflict of interest to the main topic of this report. Membership of a stakeholder group on which the results
Comparative effect of statins and type of physical exercises on vascular health: a meta-synthesis of evidence Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files
High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in East Asian patients undergoing percutaneous coronary intervention: a meta-analysis of eighteen randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate
What is the association between statins, when prescribed for primary or secondary prevention of cardiovascular disease, and key outcomes for community dwelling older adults living with frailty? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears
The effects of different statins on glucose, HbA1c and new-onset diabetes: A systematic review and network meta-analysis. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any
Effects of perioperative statin use on postoperative cardiovascular complications in patients undergoing cardiac surgery: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration
Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Many guidelines use expected risk for cardiovascular disease (CVD) during the next 10 years as a basis for recommendations on use of statins for primary prevention of CVD. However, how harms were considered and weighed against benefits is often unclear.To identify the expected risk above which statins provide net benefit.Quantitative benefit-harm balance modeling (...) study.Network meta-analysis of primary prevention trials, a preference survey, and selected observational studies.Persons aged 40 to 75 years with no history of CVD.10 years.Clinicians and guideline developers.Low- or moderate-dose statin versus no statin.The 10-year risk for CVD at which statins provide at least a 60% probability of net benefit, with baseline risk, frequencies of and preferences for statin benefits and harms, and competing risk for non-CVD death taken into account.Younger men had net
Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment High-dose statin (HDS) therapy is recommended to reduce low-density lipoprotein cholesterol (LDL-C); however, some patients are unable to tolerate the associated side effects. Nutraceuticals have shown efficacy in lowering LDL-C. The aim of this study was to evaluate whether the combination of low-dose statin (LDS) plus ezetimibe (EZE) or LDS plus
Statins and Multiple Noncardiovascular Outcomes: Umbrella Review of Meta-analyses of Observational Studies and Randomized Controlled Trials. Many effects of statins on non-cardiovascular disease (non-CVD) outcomes have been reported.To evaluate the quantity, validity, and credibility of evidence regarding associations between statins and non-CVD outcomes and the effects of statins on these outcomes.MEDLINE and EMBASE (English terms only, inception to 28 May 2018).Meta-analyses (published (...) in English) of observational studies and of randomized controlled trials (RCTs) that examined non-CVD outcomes of statin intake.Two investigators extracted data from meta-analyses and individual studies. Credibility assessments based on summary effect sizes from a random-effects model, between-study heterogeneity, 95% prediction interval, small-study effect, excess significance, and credibility ceilings were devised to classify evidence.This review explored 278 unique non-CVD outcomes from 112 meta
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Elevated lipoprotein(a) is a genetic risk factor for cardiovascular disease in general population studies. However, its contribution to risk for cardiovascular events in patients with established cardiovascular disease or on statin therapy is uncertain.Patient-level data from seven randomised, placebo-controlled, statin outcomes trials (...) (a) measurements (mean age 62 years [SD 8]; 8064 [28%] women; 5751 events during 95 576 person-years at risk). Initiation of statin therapy reduced LDL cholesterol (mean change -39% [95% CI -43 to -35]) without a significant change in lipoprotein(a). Associations of baseline and on-statin treatment lipoprotein(a) with cardiovascular disease risk were approximately linear, with increased risk at lipoprotein(a) values of 30 mg/dL or greater for baseline lipoprotein(a) and 50 mg/dL or greater for on-statin
Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial Statins prevent saphenous vein graft (SVG) disease and improve outcomes after coronary artery bypass graft surgery. However, the optimal postoperative statin dose remains unclear. The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events trial was undertaken to evaluate whether early postoperative high (...) -dose statin therapy reduces SVG occlusion compared with conventional moderate-dose therapy.In this pilot, multicenter, double-blind randomized trial, 173 patients who had coronary artery bypass graft surgery with SVG were randomized to receive 10 mg or 80 mg atorvastatin daily for 1 year. The primary outcome was SVG occlusion at 1 year. Secondary outcomes were SVG stenosis and major adverse cardiovascular events.During trial enrollment, patients randomized to 80 mg atorvastatin achieved
Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. To assess whether statin treatment is associated with a reduction in atherosclerotic cardiovascular disease (CVD) and mortality in old and very old adults with and without diabetes.Retrospective cohort study.Database of the Catalan primary care system (SIDIAP), Spain, 2006-15.46 864 people aged 75 years or more without clinically (...) recognised atherosclerotic CVD. Participants were stratified by presence of type 2 diabetes mellitus and as statin non-users or new users.Incidences of atherosclerotic CVD and all cause mortality compared using Cox proportional hazards modelling, adjusted by the propensity score of statin treatment. The relation of age with the effect of statins was assessed using both a categorical approach, stratifying the analysis by old (75-84 years) and very old (≥85 years) age groups, and a continuous analysis
Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of StatinsStatins are usually well-tolerated drugs with a clear dose-dependent efficacy. However, manifestation of statin's side effects also bears a direct relation to higher doses necessary to achieve high impact cholesterol-lowering effects. Nevertheless, the reliance on statin efficacy alone has often left dietary intervention underutilized even though studies have shown (...) a reduction in serum cholesterol levels when dietary fiber intake is increased. In this meta-analysis, we investigated whether the concomitant use of psyllium, a gel-forming viscous soluble fiber, would cause further overall cholesterol lowering in subjects already receiving statins. A systematic review of the medical literature was performed and identified three randomized, controlled clinical studies that evaluated the cholesterol lowering efficacy of statins when given concomitantly with psyllium